Metronidazole Treatment Failure and Persistent BV Lead to Increased Frequencies of Activated T- and Dendritic-Cell Subsets
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design, Participants and Specimen Collection
2.2. BV Classification Using Nugent Score
2.3. 16S rRNA Gene Amplicon Sequencing and Upstream Analysis
2.4. Cytokine and Chemokine Measurement
2.5. Assessment of Immune Cell Phenotype and Activation in Endocervical Cytobrushes
2.6. Statistical Analysis
3. Results
3.1. Participant Characteristics
3.2. Shifts in Cell Phenotypes Following MDZ Treatment
3.3. Vaginal Microbiota Characteristics Pre- and Post-Metronidazole
3.4. Effect of Bacterial Community Transition Status on Cell Percentage Difference
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Shipitsyna, E.; Roos, A.; Datcu, R.; Hallen, A.; Fredlund, H.; Jensen, J.S.; Engstrand, L.; Unemo, M. Composition of the vaginal microbiota in women of reproductive age—Sensitive and specific molecular diagnosis of bacterial vaginosis is possible? PLoS ONE 2013, 8, e60670. [Google Scholar] [CrossRef] [PubMed]
- Bradshaw, C.S.; Vodstrcil, L.A.; Hocking, J.S.; Law, M.; Pirotta, M.; Garland, S.M.; De Guingand, D.; Morton, A.N.; Fairley, C.K. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2013, 56, 777–786. [Google Scholar] [CrossRef]
- Swidsinski, A.; Loening-Baucke, V.; Mendling, W.; Dörffel, Y.; Schilling, J.; Halwani, Z.; Jiang, X.F.; Verstraelen, H.; Swidsinski, S. Infection through structured polymicrobial Gardnerella biofilms (StPM-GB). Histol. Histopathol. 2014, 29, 567–587. [Google Scholar] [CrossRef]
- Swidsinski, A.; Loening-Baucke, V.; Swidsinski, S.; Verstraelen, H. Polymicrobial Gardnerella biofilm resists repeated intravaginal antiseptic treatment in a subset of women with bacterial vaginosis: A preliminary report. Arch. Gynecol. Obstet. 2015, 291, 605–609. [Google Scholar] [CrossRef] [PubMed]
- Bradshaw, C.S.; Sobel, J.D. Current Treatment of Bacterial Vaginosis—Limitations and Need for Innovation. J. Infect. Dis. 2016, 214, S14–S20. [Google Scholar] [CrossRef]
- Lev-Sagie, A.; Goldman-Wohl, D.; Cohen, Y.; Dori-Bachash, M.; Leshem, A.; Mor, U.; Strahilevitz, J.; Moses, A.E.; Shapiro, H.; Yagel, S.; et al. Vaginal microbiome transplantation in women with intractable bacterial vaginosis. Nat. Med. 2019, 25, 1500–1504. [Google Scholar] [CrossRef] [PubMed]
- Joag, V.; Obila, O.; Gajer, P.; Scott, M.C.; Dizzell, S.; Humphrys, M.; Shahabi, K.; Huibner, S.; Shannon, B.; Tharao, W.; et al. Impact of Standard Bacterial Vaginosis Treatment on the Genital Microbiota, Immune Milieu, and Ex Vivo Human Immunodeficiency Virus Susceptibility. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2019, 68, 1675–1683. [Google Scholar] [CrossRef]
- Verwijs, M.C.; Agaba, S.K.; Darby, A.C.; van de Wijgert, J. Impact of Oral Metronidazole Treatment on the Vaginal Microbiota and Correlates of Treatment Failure. Am. J. Obs. Gynecol. 2019, 222, 157.E1–157.E13. [Google Scholar] [CrossRef]
- Mtshali, A.; San, J.E.; Osman, F.; Garrett, N.; Balle, C.; Giandhari, J.; Onywera, H.; Mngomezulu, K.; Mzobe, G.; de Oliveira, T.; et al. Temporal Changes in Vaginal Microbiota and Genital Tract Cytokines Among South African Women Treated for Bacterial Vaginosis. Front. Immunol. 2021, 12, 730986. [Google Scholar] [CrossRef]
- Bostwick, D.G.; Woody, J.; Hunt, C.; Budd, W. Antimicrobial resistance genes and modelling of treatment failure in bacterial vaginosis: Clinical study of 289 symptomatic women. J. Med. Microbiol. 2016, 65, 377–386. [Google Scholar] [CrossRef]
- Barrons, R.; Tassone, D. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: A review. Clin. Ther. 2008, 30, 453–468. [Google Scholar] [CrossRef]
- Lambert, J.A.; John, S.; Sobel, J.D.; Akins, R.A. Longitudinal analysis of vaginal microbiome dynamics in women with recurrent bacterial vaginosis: Recognition of the conversion process. PLoS ONE 2013, 8, e82599. [Google Scholar] [CrossRef] [PubMed]
- Bradshaw, C.S.; Morton, A.N.; Hocking, J.; Garland, S.M.; Morris, M.B.; Moss, L.M.; Horvath, L.B.; Kuzevska, I.; Fairley, C.K. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J. Infect. Dis. 2006, 193, 1478–1486. [Google Scholar] [CrossRef] [PubMed]
- Anahtar, M.N.; Byrne, E.H.; Doherty, K.E.; Bowman, B.A.; Yamamoto, H.S.; Soumillon, M.; Padavattan, N.; Ismail, N.; Moodley, A.; Sabatini, M.E.; et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity 2015, 42, 965–976. [Google Scholar] [CrossRef]
- Gosmann, C.; Anahtar, M.N.; Handley, S.A.; Farcasanu, M.; Abu-Ali, G.; Bowman, B.A.; Padavattan, N.; Desai, C.; Droit, L.; Moodley, A.; et al. Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women. Immunity 2017, 46, 29–37. [Google Scholar] [CrossRef] [PubMed]
- Lennard, K.; Dabee, S.; Barnabas, S.L.; Havyarimana, E.; Blakney, A.; Jaumdally, S.Z.; Botha, G.; Mkhize, N.N.; Bekker, L.G.; Lewis, D.A.; et al. Microbial Composition Predicts Genital Tract Inflammation and Persistent Bacterial Vaginosis in South African Adolescent Females. Infect. Immun. 2018, 86, e00410-17. [Google Scholar] [CrossRef] [PubMed]
- Verstraelen, H.; Verhelst, R.; Claeys, G.; De Backer, E.; Temmerman, M.; Vaneechoutte, M. Longitudinal analysis of the vaginal microflora in pregnancy suggests that L. crispatus promotes the stability of the normal vaginal microflora and that L. gasseri and/or L. iners are more conducive to the occurrence of abnormal vaginal microflora. BMC Microbiol. 2009, 9, 116. [Google Scholar] [CrossRef] [PubMed]
- Masson, L.; Mlisana, K.; Little, F.; Werner, L.; Mkhize, N.N.; Ronacher, K.; Gamieldien, H.; Williamson, C.; McKinnon, L.R.; Walzl, G.; et al. Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: A cross-sectional study. Sex. Transm. Infect. 2014, 90, 580–587. [Google Scholar] [CrossRef]
- Thurman, A.R.; Kimble, T.; Herold, B.; Mesquita, P.M.; Fichorova, R.N.; Dawood, H.Y.; Fashemi, T.; Chandra, N.; Rabe, L.; Cunningham, T.D.; et al. Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity. AIDS Res. Hum. Retroviruses 2015, 31, 1139–1152. [Google Scholar] [CrossRef]
- Santos, C.M.A.; Pires, M.C.V.; Leão, T.L.; Silva, A.K.S.; Miranda, L.S.; Martins, F.S.; Silva, A.M.; Nicoli, J.R. Anti-inflammatory effect of two Lactobacillus strains during infection with Gardnerella vaginalis and Candida albicans in a HeLa cell culture model. Microbiology 2018, 164, 349–358. [Google Scholar] [CrossRef]
- Sierra, L.J.; Brown, A.G.; Barilá, G.O.; Anton, L.; Barnum, C.E.; Shetye, S.S.; Soslowsky, L.J.; Elovitz, M.A. Colonization of the cervicovaginal space with Gardnerella vaginalis leads to local inflammation and cervical remodeling in pregnant mice. PLoS ONE 2018, 13, e0191524. [Google Scholar] [CrossRef]
- Nasu, K.; Narahara, H. Pattern recognition via the toll-like receptor system in the human female genital tract. Mediat. Inflamm. 2010, 2010, 976024. [Google Scholar] [CrossRef]
- Vatanen, T.; Kostic, A.D.; d’Hennezel, E.; Siljander, H.; Franzosa, E.A.; Yassour, M.; Kolde, R.; Vlamakis, H.; Arthur, T.D.; Hämäläinen, A.M.; et al. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. Cell 2016, 165, 842–853. [Google Scholar] [CrossRef]
- Aroutcheva, A.; Ling, Z.; Faro, S. Prevotella bivia as a source of lipopolysaccharide in the vagina. Anaerobe 2008, 14, 256–260. [Google Scholar] [CrossRef] [PubMed]
- Hoermannsperger, G.; Clavel, T.; Hoffmann, M.; Reiff, C.; Kelly, D.; Loh, G.; Blaut, M.; Hölzlwimmer, G.; Laschinger, M.; Haller, D. Post-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: Impact on chronic inflammation. PLoS ONE 2009, 4, e4365. [Google Scholar] [CrossRef]
- Kyongo, J.K.; Crucitti, T.; Menten, J.; Hardy, L.; Cools, P.; Michiels, J.; Delany-Moretlwe, S.; Mwaura, M.; Ndayisaba, G.; Joseph, S.; et al. Cross-Sectional Analysis of Selected Genital Tract Immunological Markers and Molecular Vaginal Microbiota in Sub-Saharan African Women, with Relevance to HIV Risk and Prevention. Clin. Vaccine Immunol. CVI 2015, 22, 526–538. [Google Scholar] [CrossRef] [PubMed]
- Sun, S.C. The non-canonical NF-κB pathway in immunity and inflammation. Nat. Rev. Immunol. 2017, 17, 545–558. [Google Scholar] [CrossRef]
- Rizzo, A.; Fiorentino, M.; Buommino, E.; Donnarumma, G.; Losacco, A.; Bevilacqua, N. Lactobacillus crispatus mediates anti-inflammatory cytokine interleukin-10 induction in response to Chlamydia trachomatis infection in vitro. Int. J. Med. Microbiol. 2015, 305, 815–827. [Google Scholar] [CrossRef]
- Manhanzva, M.T.; Abrahams, A.G.; Gamieldien, H.; Froissart, R.; Jaspan, H.; Jaumdally, S.Z.; Barnabas, S.L.; Dabee, S.; Bekker, L.G.; Gray, G.; et al. Inflammatory and antimicrobial properties differ between vaginal Lactobacillus isolates from South African women with non-optimal versus optimal microbiota. Sci. Rep. 2020, 10, 6196. [Google Scholar] [CrossRef]
- Garrett, N.J.; Osman, F.; Maharaj, B.; Naicker, N.; Gibbs, A.; Norman, E.; Samsunder, N.; Ngobese, H.; Mitchev, N.; Singh, R.; et al. Beyond syndromic management: Opportunities for diagnosis-based treatment of sexually transmitted infections in low- and middle-income countries. PLoS ONE 2018, 13, e0196209. [Google Scholar] [CrossRef]
- France, M.T.; Ma, B.; Gajer, P.; Brown, S.; Humphrys, M.S.; Holm, J.B.; Waetjen, L.E.; Brotman, R.M.; Ravel, J. VALENCIA: A nearest centroid classification method for vaginal microbial communities based on composition. Microbiome 2020, 8, 166. [Google Scholar] [CrossRef]
- McKinnon, L.R.; Nyanga, B.; Chege, D.; Izulla, P.; Kimani, M.; Huibner, S.; Gelmon, L.; Block, K.E.; Cicala, C.; Anzala, A.O.; et al. Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility. J. Immunol. 2011, 187, 6032–6042. [Google Scholar] [CrossRef]
- Nkwanyana, N.N.; Gumbi, P.P.; Roberts, L.; Denny, L.; Hanekom, W.; Soares, A.; Allan, B.; Williamson, A.L.; Coetzee, D.; Olivier, A.J. Impact of human immunodeficiency virus 1 infection and inflammation on the composition and yield of cervical mononuclear cells in the female genital tract. Immunology 2009, 128, e746–e757. [Google Scholar] [CrossRef]
- Perfetto, S.P.; Chattopadhyay, P.K.; Roederer, M. Seventeen-colour flow cytometry: Unravelling the immune system. Nat. Rev. Immunol. 2004, 4, 648–655. [Google Scholar] [CrossRef] [PubMed]
- Masson, L.; Passmore, J.-A.S.; Liebenberg, L.J.; Werner, L.; Baxter, C.; Arnold, K.B.; Williamson, C.; Little, F.; Mansoor, L.E.; Naranbhai, V.; et al. Genital Inflammation and the Risk of HIV Acquisition in Women. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2015, 61, 260–269. [Google Scholar] [CrossRef]
- McKinnon, L.R.; Liebenberg, L.J.; Yende-Zuma, N.; Archary, D.; Ngcapu, S.; Sivro, A.; Nagelkerke, N.; Garcia Lerma, J.G.; Kashuba, A.D.; Masson, L.; et al. Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. Nat. Med. 2018, 24, 491–496. [Google Scholar] [CrossRef] [PubMed]
- Masson, L.; Arnold, K.B.; Little, F.; Mlisana, K.; Lewis, D.A.; Mkhize, N.; Gamieldien, H.; Ngcapu, S.; Johnson, L.; Lauffenburger, D.A. Inflammatory cytokine biomarkers to identify women with asymptomatic sexually transmitted infections and bacterial vaginosis who are at high risk of HIV infection. Sex. Transm. Infect. 2016, 92, 186–193. [Google Scholar] [CrossRef]
- Shattock, R.J.; Haynes, B.F.; Pulendran, B.; Flores, J.; Esparza, J. Improving defences at the portal of HIV entry: Mucosal and innate immunity. PLoS Med. 2008, 5, e81. [Google Scholar] [CrossRef]
- Steinman, R.M.; Hemmi, H. Dendritic cells: Translating innate to adaptive immunity. Innate Immun. Immunol. Mem. 2006, 311, 17–58. [Google Scholar]
- Guermonprez, P.; Valladeau, J.; Zitvogel, L.; Théry, C.; Amigorena, S. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 2002, 20, 621–667. [Google Scholar] [CrossRef]
- Pulendran, B.; Tang, H.; Manicassamy, S. Programming dendritic cells to induce TH2 and tolerogenic responses. Nat. Immunol. 2010, 11, 647–655. [Google Scholar] [CrossRef]
- Tada, H.; Aiba, S.; Shibata, K.-I.; Ohteki, T.; Takada, H. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect. Immun. 2005, 73, 7967–7976. [Google Scholar] [CrossRef]
- Basavaprabhu, H.; Sonu, K.; Prabha, R. Mechanistic insights into the action of probiotics against bacterial vaginosis and its mediated preterm birth: An overview. Microb. Pathog. 2020, 141, 104029. [Google Scholar] [CrossRef]
- Lehtoranta, L.; Hibberd, A.A.; Reimari, J.; Junnila, J.; Yeung, N.; Maukonen, J.; Crawford, G.; Ouwehand, A.C. Recovery of Vaginal Microbiota After Standard Treatment for Bacterial Vaginosis Infection: An Observational Study. Microorganisms 2020, 8, 875. [Google Scholar] [CrossRef]
- Munoz, A.; Hayward, M.R.; Bloom, S.M.; Rocafort, M.; Ngcapu, S.; Mafunda, N.A.; Xu, J.; Xulu, N.; Dong, M.; Dong, K.L.; et al. Modeling the temporal dynamics of cervicovaginal microbiota identifies targets that may promote reproductive health. Microbiome 2021, 9, 163. [Google Scholar] [CrossRef]
- Petrova, M.I.; Lievens, E.; Malik, S.; Imholz, N.; Lebeer, S. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Front. Physiol. 2015, 6, 81. [Google Scholar] [CrossRef] [PubMed]
- Nilsen, T.; Swedek, I.; Lagenaur, L.A.; Parks, T.P. Novel Selective Inhibition of Lactobacillus iners by Lactobacillus-Derived Bacteriocins. Appl. Environ. Microbiol. 2020, 86, e01594-20. [Google Scholar] [CrossRef] [PubMed]
- Cohen, C.R.; Wierzbicki, M.R.; French, A.L.; Morris, S.; Newmann, S.; Reno, H.; Green, L.; Miller, S.; Powell, J.; Parks, T.; et al. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. N. Engl. J. Med. 2020, 382, 1906–1915. [Google Scholar] [CrossRef] [PubMed]
- Shey, M.S.; Maharaj, N.; Archary, D.; Ngcapu, S.; Garrett, N.; Abdool Karim, S.; Passmore, J.A. Modulation of Female Genital Tract-Derived Dendritic Cell Migration and Activation in Response to Inflammatory Cytokines and Toll-Like Receptor Agonists. PLoS ONE 2016, 11, e0155668. [Google Scholar] [CrossRef]
- Viallard, J.; Bloch-Michel, C.; Neau-Cransac, M.; Taupin, J.; Garrigue, S.; Miossec, V.; Mercie, P.; Pellegrin, J.; Moreau, J. HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2001, 125, 485–491. [Google Scholar] [CrossRef]
- Viallard, J.-F.; Blanco, P.; André, M.; Etienne, G.; Liferman, F.; Neau, D.; Vidal, E.; Moreau, J.-F.; Pellegrin, J.-L. CD8+ HLA-DR+ T lymphocytes are increased in common variable immunodeficiency patients with impaired memory B-cell differentiation. Clin. Immunol. 2006, 119, 51–58. [Google Scholar] [CrossRef] [PubMed]
- Ramzaoui, S.; Jouen-Beades, F.; Gilbert, D.; Borsa-Lebas, F.; Michel, Y.; Humbert, G.; Tron, F. During HIV infection, CD4+ CD38+ T-cells are the predominant circulating CD4+ subset whose HLA-DR positivity increases with disease progression and whose V beta repertoire is similar to that of CD4+ CD38− T-cells. Clin. Immunol. Immunopathol. 1995, 77, 33–41. [Google Scholar] [CrossRef] [PubMed]
- Fromentin, R.; Bakeman, W.; Lawani, M.B.; Khoury, G.; Hartogensis, W.; DaFonseca, S.; Killian, M.; Epling, L.; Hoh, R.; Sinclair, E.; et al. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathog. 2016, 12, e1005761. [Google Scholar] [CrossRef] [PubMed]
Variable | Level | Baseline | 6 Weeks | 12 Weeks |
---|---|---|---|---|
N | 32 | - | - | |
Age, median [IQR] | 24 [21, 28] | - | - | |
Condom use, n (%) | No | 9 (28.1) | - | - |
Yes | 23 (71.9) | - | - | |
Frequent use of condom, n (%) | Always | 2 (6.2) | - | - |
Sometimes | 20 (62.5) | - | - | |
Never | 10 (31.2) | - | - | |
Contraceptive use, n (%) | No | 17 (53.1) | - | - |
Yes | 15 (46.9) | - | - | |
Contraception type, n (%) | Oral | 1 (3.1) | - | - |
Injectable | 10 (31.2) | - | - | |
Implant | 4 (12.5) | - | - | |
None | 17 (53.1) | - | - | |
BV score category, n (%) | Positive | 20 (62.5) | 13 (40.6) | 12 (37.5) |
Intermediate | 12 (37.5) | 11 (34.4) | 12 (37.5) | |
Negative | 0 (0.0) | 8 (25.0) | 8 (25.0) | |
BV community state type, n (%) | I | 0 (0.0) | 1 (3.1) | 2 (6.2) |
III | 11 (34.4) | 13 (40.6) | 14 (43.8) | |
IV-B | 11 (34.4) | 11 (34.4) | 11 (34.4) | |
IV-A | 10 (31.2) | 7 (21.9) | 5 (15.6) | |
Genital inflammation, n (%) | No | 23 (71.9) | 25 (78.1) | 26 (81.2) |
Yes | 9 (28.1) | 7 (21.9) | 6 (18.8) | |
Previous sexual activity, n (%) | No | 25 (78.1) | 22 (71.0) | 20 (74.1) |
Yes | 7 (21.9) | 9 (29.0) | 7 (25.9) | |
Candidiasis, n (%) | No | 27 (84.4) | 28 (87.5) | 26 (81.2) |
Yes | 5 (15.6) | 4 (12.5) | 6 (18.8) | |
Any STI, n (%) | No | 12 (37.5) | 26 (81.2) | 24 (75.0) |
Yes | 20 (62.5) | 6 (18.8) | 8 (25.0) | |
Trichomoniasis, n (%) | Negative | 28 (87.5) | 31 (96.9) | 32 (100.0) |
Positive | 4 (12.5) | 1 (3.1) | 0 (0.0) | |
Gonorrhea, n (%) | Negative | 28 (87.5) | 32 (100.0) | 31 (96.9) |
Positive | 4 (12.5) | 0 (0.0) | 1 (3.1) | |
Chlamydia, n (%) | Negative | 21 (65.6) | 31 (96.9) | 32 (100.0) |
Positive | 11 (34.4) | 1 (3.1) | 0 (0.0) | |
Herpes simplex virus type 2, n (%) | Negative | 31 (96.9) | 31 (96.9) | 31 (96.9) |
Positive | 1 (3.1) | 1 (3.1) | 1 (3.1) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Qulu, W.P.; Mzobe, G.; Mtshali, A.; Letsoalo, M.P.; Osman, F.; San, J.E.; Kama, A.O.; Garrett, N.; Mindel, A.; Rompalo, A.; et al. Metronidazole Treatment Failure and Persistent BV Lead to Increased Frequencies of Activated T- and Dendritic-Cell Subsets. Microorganisms 2023, 11, 2643. https://doi.org/10.3390/microorganisms11112643
Qulu WP, Mzobe G, Mtshali A, Letsoalo MP, Osman F, San JE, Kama AO, Garrett N, Mindel A, Rompalo A, et al. Metronidazole Treatment Failure and Persistent BV Lead to Increased Frequencies of Activated T- and Dendritic-Cell Subsets. Microorganisms. 2023; 11(11):2643. https://doi.org/10.3390/microorganisms11112643
Chicago/Turabian StyleQulu, Wenkosi Perez, Gugulethu Mzobe, Andile Mtshali, Marothi Peter Letsoalo, Farzana Osman, James Emmanuel San, Asavela Olona Kama, Nigel Garrett, Adrian Mindel, Anne Rompalo, and et al. 2023. "Metronidazole Treatment Failure and Persistent BV Lead to Increased Frequencies of Activated T- and Dendritic-Cell Subsets" Microorganisms 11, no. 11: 2643. https://doi.org/10.3390/microorganisms11112643